Cancer associated fibroblast-derived hepatocyte growth factor inhibits the paclitaxel-induced apoptosis of lung cancer A549 cells by up-regulating the PI3K/Akt and GRP78 signaling on a microfluidic platform

PLoS ONE

Volumn 10, Issue 6, 2015, Pages

  Ying, Li ^a   Zhu, Ziwei ^a   Xu, Zhiyun ^a   He, Tianrui ^b   Li, Encheng ^a   Guo, Zhe ^a   Liu, Fen ^a   Jiang, Chunmeng ^a   Wang, Qi ^a  

^a DALIAN MEDICAL UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; GLUCOSE REGULATED PROTEIN 78; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SCATTER FACTOR; FIBROBLAST GROWTH FACTOR; HEAT SHOCK PROTEIN; MOLECULAR CHAPERONE GRP78;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL ACTIVATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG FIBROBLAST; MICROFLUIDICS; MOUSE; NON SMALL CELL LUNG CANCER; NONHUMAN; PROTEIN EXPRESSION; UPREGULATION; ANIMAL; CELL CULTURE TECHNIQUE; DISEASE MODEL; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; FIBROBLAST; METABOLISM; NEOPLASM; PATHOLOGY; PROCEDURES; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, NEOPLASM; ENZYME ACTIVATION; FIBROBLAST GROWTH FACTORS; FIBROBLASTS; HEAT-SHOCK PROTEINS; HUMANS; MICROFLUIDICS; NEOPLASMS; PACLITAXEL; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84938347800     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0129593     Document Type: Article

References (37)

1. Wang J, Zhang J, Zhang L, Zhao L, Fan S, Yang Z, et al. Expression of P-gp, MRP, LRP, GST-pi and TopoIIalpha and intrinsic resistance in human lung cancer cell lines. Oncology reports. 2011; 26 (5):1081-9. doi: 10.3892/or.2011.1405 PMID: 21805041
2. Shimomura M, Yaoi T, Itoh K, Kato D, Terauchi K, Shimada J, et al. Drug resistance to paclitaxel is not only associated with ABCB1 mRNA expression but also with drug accumulation in intracellular compartments in human lung cancer cell lines. International journal of oncology. 2012; 40(4):995-1004. doi: 10.3892/ijo.2011.1297 PMID: 22179563
3. Franses JW, Baker AB, Chitalia VC, Edelman ER. Stromal endothelial cells directly influence cancer progression. Science translational medicine. 2011; 3(66):66ra5.
4. Huang B, Lei Z, Zhang GM, Li D, Song C, Li B, et al. SCF-mediated mast cell infiltration and activation exacerbate the inflammation and immunosuppression in tumor microenvironment. Blood. 2008; 112 (4):1269-79. doi: 10.1182/blood-2008-03-147033 PMID: 18524989
5. Pietras K, Ostman A. Hallmarks of cancer: interactions with the tumor stroma. Experimental cell research. 2010; 316(8):1324-31. doi: 10.1016/j.yexcr.2010.02.045 PMID: 20211171
6. Sos ML, Fischer S, Ullrich R, Peifer M, Heuckmann JM, Koker M, et al. Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer. Proc Natl Acad Sci U S A. 2009; 106(43):18351-6. doi: 10.1073/pnas.0907325106 PMID: 19805051
7. Perego P, Cossa G, Zuco V, Zunino F. Modulation of cell sensitivity to antitumor agents by targeting survival pathways. Biochemical pharmacology. 2010; 80(10):1459-65. doi: 10.1016/j.bcp.2010.07.030 PMID: 20688050
8. Yamada T, Matsumoto K, Wang W, Li Q, Nishioka Y, Sekido Y, et al. Hepatocyte growth factor reduces susceptibility to an irreversible epidermal growth factor receptor inhibitor in EGFR-T790M mutant lung cancer. Clin Cancer Res. 2010; 16(1):174-83. doi: 10.1158/1078-0432.CCR-09-1204 PMID: 20008840
9. Jagadeeswaran R, Jagadeeswaran S, Bindokas VP, Salgia R. Activation of HGF/c-Met pathway contributes to the reactive oxygen species generation and motility of small cell lung cancer cells. Am J Physiol Lung Cell Mol Physiol. 2007; 292(6):L1488-94. PMID: 17322284
10. Mendoza MC, Er EE, Blenis J. The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends in biochemical sciences. 2011; 36(6):320-8. doi: 10.1016/j.tibs.2011.03.006 PMID: 21531565
11. Healy SJ, Gorman AM, Mousavi-Shafaei P, Gupta S, Samali A. Targeting the endoplasmic reticulum-stress response as an anticancer strategy. European journal of pharmacology. 2009; 625(1-3):234-46. doi: 10.1016/j.ejphar.2009.06.064 PMID: 19835867
12. Lee AS. The ER chaperone and signaling regulator GRP78/BiP as a monitor of endoplasmic reticulum stress. Methods. 2005; 35(4):373-81. PMID: 15804610
13. Lee E, Nichols P, Spicer D, Groshen S, Yu MC, Lee AS. GRP78 as a novel predictor of responsiveness to chemotherapy in breast cancer. Cancer Res. 2006; 66(16):7849-53. PMID: 16912156
14. Su SF, Chang YW, Andreu-Vieyra C, Fang JY, Yang Z, Han B, et al. miR-30d, miR-181a and miR-199a-5p cooperatively suppress the endoplasmic reticulum chaperone and signaling regulator GRP78 in cancer. Oncogene. 2013; 32(39):4694-701. doi: 10.1038/onc.2012.483 PMID: 23085757
15. Wey S, Luo B, Tseng CC, Ni M, Zhou H, Fu Y, et al. Inducible knockout of GRP78/BiP in the hematopoietic system suppresses Pten-null leukemogenesis and AKT oncogenic signaling. Blood. 2012; 119 (3):817-25. doi: 10.1182/blood-2011-06-357384 PMID: 21937694
16. Zhao L, Wang Z, Fan S, Meng Q, Li B, Shao S, et al. Chemotherapy resistance research of lung cancer based on micro-fluidic chip system with flow medium. Biomed Microdevices. 2010; 12(2):325-32. doi: 10.1007/s10544-009-9388-3 PMID: 20066497
17. Pfaffenbach KT, Pong M, Morgan TE, Wang H, Ott K, Zhou B, et al. GRP78/BiP is a novel downstream target of IGF-1 receptor mediated signaling. J Cell Physiol. 2012; 227(12):3803-11. doi: 10.1002/jcp.24090 PMID: 22422508
18. Wu MH, Huang SB, Lee GB. Microfluidic cell culture systems for drug research. Lab Chip. 2010; 10 (8):939-56. doi: 10.1039/b921695b PMID: 20358102
19. Bauer M, Su G, Beebe DJ, Friedl A. 3D microchannel co-culture: method and biological validation. Integr Biol (Camb). 2010; 2(7-8):371-8.
20. Carraro A, Hsu WM, Kulig KM, Cheung WS, Miller ML, Weinberg EJ, et al. In vitro analysis of a hepatic device with intrinsic microvascular-based channels. Biomed Microdevices. 2008; 10(6):795-805. doi: 10.1007/s10544-008-9194-3 PMID: 18604585
21. Liu L, Loutherback K, Liao D, Yeater D, Lambert G, Estevez-Torres A, et al. A microfluidic device for continuous cancer cell culture and passage with hydrodynamic forces. Lab Chip. 2010; 10(14):1807-13. doi: 10.1039/c003509b PMID: 20424729
22. Ng CP, Pun SH. A perfusable 3D cell-matrix tissue culture chamber for in situ evaluation of nanoparticle vehicle penetration and transport. Biotechnol Bioeng. 2008; 99(6):1490-501. PMID: 17969174
23. Huang CP, Lu J, Seon H, Lee AP, Flanagan LA, Kim HY, et al. Engineering microscale cellular niches for three-dimensional multicellular co-cultures. Lab Chip. 2009; 9(12):1740-8. doi: 10.1039/b818401a PMID: 19495458
24. Ying L, Wang Q. Microfluidic chip-based technologies: emerging platforms for cancer diagnosis. BMC biotechnology. 2013; 13:76. doi: 10.1186/1472-6750-13-76 PMID: 24070124
25. Siyan W, Feng Y, Lichuan Z, Jiarui W, Yingyan W, Li J, et al. Application of microfluidic gradient chip in the analysis of lung cancer chemotherapy resistance. J Pharm Biomed Anal. 2009; 49(3):806-10. doi: 10.1016/j.jpba.2008.12.021 PMID: 19162424
26. Duffy DC, McDonald JC, Schueller OJ, Whitesides GM. Rapid Prototyping of Microfluidic Systems in Poly(dimethylsiloxane). Anal Chem. 1998; 70(23):4974-84. doi: 10.1021/ac980656z PMID: 21644679
27. Kinoshita K, Nakagawa K, Hamada J, Hida Y, Tada M, Kondo S, et al. Imatinib mesylate inhibits the proliferation-stimulating effect of human lung cancer-associated stromal fibroblasts on lung cancer cells. International journal of oncology. 2010; 37(4):869-77. PMID: 20811709
28. Hao Y, Zhang L, He J, Guo Z, Ying L, Xu Z, et al. Functional investigation of NCI-H460-inducible myofibroblasts on the chemoresistance to VP-16 with a microfluidic 3D co-culture device. PLoS One. 2013; 8(4):e61754. doi: 10.1371/journal.pone.0061754 PMID: 23613925
29. Wang Y, Wang W, Wang S, Wang J, Shao S, Wang Q. Down-regulation of GRP78 is associated with the sensitivity of chemotherapy to VP-16 in small cell lung cancer NCI-H446 cells. BMC Cancer. 2008; 8:372. doi: 10.1186/1471-2407-8-372 PMID: 19087354
30. Fujiwara M, Izuishi K, Sano T, Hossain MA, Kimura S, Masaki T, et al. Modulating effect of the PI3-kinase inhibitor LY294002 on cisplatin in human pancreatic cancer cells. Journal of experimental & clinical cancer research: CR. 2008; 27:76.
31. Gunn RM, Hailes HC. Insights into the PI3-K-PKB-mTOR signalling pathway from small molecules. Journal of chemical biology. 2008; 1(1-4):49-62. doi: 10.1007/s12154-008-0008-0 PMID: 19568798
32. Radisky DC. Fibroblasts act as co-conspirators for chemotherapy resistance. Cancer Biol Ther. 2008; 7 (9):1348-9. PMID: 18787412
33. Tachibana K, Minami Y, Shiba-Ishii A, Kano J, Nakazato Y, Sato Y, et al. Abnormality of the hepatocyte growth factor/MET pathway in pulmonary adenocarcinogenesis. Lung Cancer. 75(2):181-8. doi: 10.1016/j.lungcan.2011.07.008 PMID: 21872356
34. Beaver LM, Stemmy EJ, Schwartz AM, Damsker JM, Constant SL, Ceryak SM, et al. Lung inflammation, injury, and proliferative response after repetitive particulate hexavalent chromium exposure. Environmental health perspectives. 2009; 117(12):1896-902. doi: 10.1289/ehp.0900715 PMID: 20049209
35. Brennen WN, Isaacs JT, Denmeade SR. Rationale behind targeting fibroblast activation protein-expressing carcinoma-associated fibroblasts as a novel chemotherapeutic strategy. Molecular cancer therapeutics. 2012; 11(2):257-66. doi: 10.1158/1535-7163.MCT-11-0340 PMID: 22323494
36. Whitesides GM. The origins and the future of microfluidics. Nature. 2006; 442(7101):368-73. PMID: 16871203
37. Lee PJ, Hung PJ, Rao VM, Lee LP. Nanoliter scale microbioreactor array for quantitative cell biology. Biotechnol Bioeng. 2006; 94(1):5-14. PMID: 16315325